Evidence map›Paper›PMID 35187287›Full record

ReviewJournal of clinical and translational research2022

COVID-19-associated mucormycosis of head-and-neck region: A systematic review.

Mamata Kamat, Uma Datar, Sanjay Byakodi, Sharad Kamat, Varsha Vimal Kumar

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in Journal of clinical and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. COVID-19 and Fungal Diseases.Antibiotics (Basel, Switzerland) · 2022
    Review
  7. COVID-19 Associated Mucormycosis (CAM): A Single Hospital-Based Study.Journal of oral and maxillofacial pathology : JOMFP
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mamata KamatDepartment of Oral and Maxillofacial Pathology, BV(DU) Dental College and Hospital, Sangli, Maharashtra, India.
Uma DatarDepartment of Oral and Maxillofacial Pathology, BV(DU) Dental College and Hospital, Sangli, Maharashtra, India.
Sanjay ByakodiDepartment of Oral and Maxillofacial Surgery, BV(DU) Dental College and Hospital, Sangli, Maharashtra, India.
Sharad KamatDepartment of Conservative Dentistry and Endodontics, BV(DU) Dental College and Hospital, Sangli, Maharashtra, India.
Varsha Vimal KumarDepartment of Oral and Maxillofacial Pathology, Rajarajeswari Dental College and Hospital, Bengaluru, Karnataka, India.
Rajarajeswari Dental College and Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimWith the second wave of COVID-19, there has been a substantial rise in opportunistic infections like mucormycosis. Mucormycosis is a fatal fungal infection and understanding the associated risk factors and their management plays a key role to reduce mortality and morbidity caused due to such infections. This systematic review was conducted to assess the risk factors, clinical characteristics and to understand the pathogenesis of COVID-19-associated mucormycosis (CAM) affecting the head-and-neck region.

methodsThe PubMed database was searched with the keywords; ((Mucormycosis) OR (invasive fungal sinusitis)) AND (COVID-19) and the PRISMA chart was prepared for the selection of the reports based on the inclusion and exclusion criteria.

resultsA total of 261 cases of CAM affecting the head-and-neck region were analyzed in this systematic review. Most of the patients presented with rhino-orbital/rhino-orbito-cerebral form of mucormycosis (rhino-orbital mucormycosis/rhino-orbital-cerebral mucormycosis). Pulmonary mucormycosis along with rhino-orbital form, involvement of hard palate, and maxillary sinus was seen in one case each. A total of 224 (85.8%) patients were diabetic, 68 (30.3%) of them had poor glycemic control. Steroids were administered in 210 (80.4%) patients. Except for two, antifungal treatment was given to all patients. Follow-up data revealed 67 (25.6%) deaths and 193 (73.9%) were alive with one patient lost during follow-up.

conclusionThe findings of this systematic review suggested that the occurrence of mucormycosis in COVID-19 patients is related to the inherent effects of COVID-19 infection on the immune system, comorbidities especially diabetes, and treatment aspects. Hence, a detailed understanding of these factors may aid in the personalized management of CAM and improve the disease outcome. RELEVANCE FOR PATIENTS: The risk factors in patients affected by CAM should be recognized and closely monitored in post-COVID-19 patients. A multidisciplinary team must be in place to reduce the mortality and morbidity in such patients.

Indexed as

COVID-19diabetes mellitusmucormycosissteroids

Identifiers

PMID35187287
PMCPMC8848761
OpenAlexW4213393273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.